Magenlom

Omeprazole, the active ingredient in Magenlom, is a proton pump inhibitor presented as an oral dosage form for oral use. It is employed to reduce gastric acid production in adults with conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, and other acid‑related disorders.

GNH USA supplies Magenlom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor used to manage disorders associated with excess gastric acid secretion.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic therapy by suppressing acid. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine condition.

Adverse reactions to omeprazole can range from mild to severe. Awareness of common and serious events helps clinicians monitor therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools occurring intermittently. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild cramping or discomfort.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty. - Clostridioides difficile infection: persistent watery diarrhea with abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, seizures, or cardiac arrhythmia. - Bone fracture risk: increased incidence of hip, wrist, or spine fractures with long‑term use. - Stevens‑Johnson syndrome: painful skin lesions and mucosal involvement.

When prescribing omeprazole, consider the following safety measures.

- Assess renal function: adjust use in patients with severe renal impairment. - Monitor magnesium levels: especially during prolonged therapy. - Use lowest effective dose: limit duration to the shortest period necessary. - Avoid long‑term use unless clearly indicated: reassess need periodically. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic antiviral levels. - Methotrexate: increased systemic exposure, raising toxicity potential.

Moderate Interactions (Monitor Closely): - Warfarin: possible elevation of INR, requiring more frequent coagulation monitoring. - Digoxin: may increase serum concentrations, necessitating dose adjustment.